Iclusig™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

ICLUSIG is indicated for the treatment of adult patients with:,Chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid Ieukaemia (CML) whose disease is resistant to, or who are intolerant of at least two prior tyrosine kinase inhibitors; or where there is a T315I mutation.,Philadelphia chromosome positive acute lymphoblastic Ieukaemia (Ph+ ALL) whose disease is resistant to, or who are intolerant of dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or where there is a T315I mutation.,Therapy with ICLUSIG should be initiated and monitored by a haematologist with expertise in managing adult Ieukaemias.

Source: ARTG

• Shelf lifetime is 36 Months
• Store below 30 degrees Celsius
• Protect from Light; Store in Original Container

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Tablet, film coated
• Oral
• Tablets are white, biconvex, round film-coated tablets debossed with 'A5' on one side.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• Bottles of 30 tablets
• Bottles of 60 tablets

Source: ARTG

This medicine is not listed on the Pharmaceutical Benefits Scheme (PBS). Talk to your pharmacist about how much it will cost.

Source: PBS

For the active ingredient: ponatinib

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).